Form 4: Aspira Women's Health Director, Stefanie Cavanaugh, Reports Stock Transactions

Director Stefanie Cavanaugh of Aspira Women's Health Inc. reports the vesting and conversion of restricted stock units into common stock.

Summary

• Stefanie Cavanaugh, a director at Aspira Women's Health Inc., reported a transaction involving restricted stock units (RSUs).
• On December 31, 2024, 5,937 RSUs vested and were converted into 5,937 shares of common stock.
• These RSUs were part of a grant of 23,750 RSUs awarded on August 22, 2024.
• Following the transaction, Ms. Cavanaugh directly owns 66,851 shares of common stock and 11,875 RSUs.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider transactions, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the holdings of company directors.

Comparison to Industry Standards

• The reporting of insider transactions via SEC Form 4 is a standard practice for all publicly traded companies in the United States.
• The vesting and conversion of RSUs is a common form of equity compensation for directors and executives.
• The level of detail provided in the form is consistent with SEC requirements and industry norms.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects a change in ownership by a director.
• The transaction is part of the director's compensation package.

Key Dates

Keywords

Aspira Women's Health, stock transaction, restricted stock units, RSUs, insider trading, beneficial ownership, director, SEC Form 4